Rapport Therapeutics Hits New 52-Week High As RAP-219 Advances Into Phase 3

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results

Ionis Pharmaceuticals (IONS) shares have fallen over 40% this year, despite analysts maintaining an average price target of $83.82. The company has six approved therapies, primarily for rare diseases, and is developing eight more in late-stage trials. Ionis reported a 40.7% revenue decline and a net loss in Q2, but analysts highlight its antisense oligonucleotide technology and potential for future growth.

GLOBALFOUNDRIES (GFS) secured $375M in CHIPS R&D funding and $300M for silicon photonics. Its stock rose 4.32% recently, but is down 46.67% over 90 days. Analysts value it at $76, 37% above its last close of $47.82, citing its global manufacturing and government incentives. However, risks include weak smartphone demand and high capital spending.

Summit Therapeutics (SMMT) reported a 27% reduction in death risk for its drug ivonescimab in a lung cancer trial, compared to Merck’s Keytruda. The company has a high P/S ratio (~370x) and a GF Score of 30/100, indicating financial challenges. Insiders have bought $114.6M in shares over 12 months, signaling confidence.

Nvidia CEO Jensen Huang forecasted a doubling of chip sales next year, citing supply chain capabilities as the key factor. The company's official guidance projects 70% revenue growth for FY2028. Nvidia is investing in supply chain AI with Palantir and expanding partnerships to address bottlenecks. The forecast depends on overcoming supply constraints, not just demand.

Apple (AAPL) launched iPhone 18 Pro models with higher price points, marking its first major release under CEO John Ternus. Bank of America analyst Wamsi Mohan reiterated a Buy rating with a $370 price target, citing strong upgrade cycles and AI opportunities. Apple is reportedly developing AI servers using Nvidia's (NVDA) NVLink Fusion technology. Samsung (SSNLF) reclaimed the top spot in global smartphone shipments. Elon Musk's xAI and X Corp dropped Apple from their antitrust lawsuit.